Bright Minds Biosciences (DRUG) Net Income towards Common Stockholders: 2019-2021
Historic Net Income towards Common Stockholders for Bright Minds Biosciences (DRUG) over the last 1 years, with Jun 2021 value amounting to $3.2 million.
- Bright Minds Biosciences' Net Income towards Common Stockholders rose 18524.75% to $3.2 million in Q2 2021 from the same period last year, while for Jun 2021 it was $4.0 million, marking a year-over-year change of. This contributed to the annual value of -$477,865 for FY2020, which is 1818.26% down from last year.
- Bright Minds Biosciences' Net Income towards Common Stockholders amounted to $3.2 million in Q2 2021, which was up 681.59% from $405,879 recorded in Q1 2021.
- In the past 5 years, Bright Minds Biosciences' Net Income towards Common Stockholders ranged from a high of $3.2 million in Q2 2021 and a low of $17,033 during Q2 2020.
- Its 3-year average for Net Income towards Common Stockholders is $681,365, with a median of $216,674 in 2020.
- Data for Bright Minds Biosciences' Net Income towards Common Stockholders shows a peak YoY soared of 18,524.75% (in 2021) over the last 5 years.
- Bright Minds Biosciences' Net Income towards Common Stockholders (Quarterly) stood at $59,638 in 2019, then soared by 257.66% to $220,046 in 2020, then spiked by 18,524.75% to $3.2 million in 2021.
- Its last three reported values are $3.2 million in Q2 2021, $405,879 for Q1 2021, and $220,046 during Q4 2020.